Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
15 pending office actions • 10 art units • 13 examiners • 0 of 15 (0%) have an AI response strategy ready • 14 patents granted in the last 365 days
MannKind Corporation manages a significant portfolio with 16 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 14 distinct examiners and 10 distinct art units. The busiest examiner, OLSEN, KAELEIGH ELIZABETH, is responsible for 2 busiest examiner pending actions.
The presence of 10 distinct art units indicates a broad technical scope within the biotech and pharma sectors. With 14 distinct examiners involved, the company's prosecution strategy is highly diversified, reducing the impact of any single examiner's decisions. Because OLSEN, KAELEIGH ELIZABETH handles only 2 of the 16 pending office actions, the portfolio's success is spread across many different examination dockets. This level of activity across 10 distinct art units requires a sophisticated approach to maintain consistency across various pharmaceutical classifications. For a portfolio with this many pending matters, the administrative burden of tracking 14 distinct examiners is substantial, but it provides a hedge against the idiosyncratic tendencies of any one individual at the USPTO.
Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (13%) |
| §103 only | 2 (13%) |
| Double-patenting only | 1 (7%) |
| Double-patenting + other | 4 (27%) |
| Multi-statute (no §101) | 4 (27%) |
| No statute on record | 2 (13%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| OLSEN, KAELEIGH ELIZABETH | 2 | 50.0% | +61.5% |
| HAGHIGHATIAN, MINA | 2 | 46.1% | +39.3% |
| TCHERKASSKAYA, OLGA V | 1 | 55.4% | +46.2% |
| ROBINSON, KYLE G | 1 | 11.7% | +16.6% |
| HIBBERT, CATHERINE S | 1 | 58.9% | +48.8% |
| CHANDRA, GYAN | 1 | 71.3% | +27.5% |
| HOLLAND, PAUL J | 1 | 57.5% | +64.6% |
| WEBB, WALTER E | 1 | 46.3% | +18.8% |
| PIHONAK, SARAH | 1 | 61.3% | +42.6% |
| KRISHNAN, GANAPATHY | 1 | 52.8% | +1.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17016158 | METHOD AND COMPOSITION FOR ADMINISTERING PROSTAGLANDINS | MCDOWELL, BRIAN E | 9d |
| 18861479 | METHOD AND COMPOSITION FOR TREATING LUNG DISEASES | TCHERKASSKAYA, OLGA V | — |
| 18847985 | OPTIMIZATION OF DOSING AND PRESCRIBING OF MEDICATION | ROBINSON, KYLE G | — |
| 18796217 | METHOD AND COMPOSITION FOR TREATING OBESITY | OLSEN, KAELEIGH ELIZABETH | — |
| 17996706 | CLOFAZIMINE COMPOSITION AND METHOD FOR THE TREATMENT OR PROPHYLAXIS OF VIRAL INFECTIONS | OLSEN, KAELEIGH ELIZABETH | — |
| 17755425 | Compositions of Clofazimine, Combinations Comprising Them, Processes for Their Preparation, Uses and Methods of Treatment Comprising Them | ARNOLD, ERNST V | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17983915 | DRY POWDER INHALER | HAGHIGHATIAN, MINA | 1d overdue |
| 18367118 | METHOD FOR IMPROVING THE PHARMACEUTIC PROPERTIES OF MICROPARTICLES COMPRISING DIKETOPIPERAZINE AND AN ACTIVE AGENT | WEBB, WALTER E | 34d |
| 18265660 | Method and Composition for Treating Pulmonary Fibrosis | PIHONAK, SARAH | 61d |
| 18861479 | METHOD AND COMPOSITION FOR TREATING LUNG DISEASES | TCHERKASSKAYA, OLGA V | — |
| 18847985 | OPTIMIZATION OF DOSING AND PRESCRIBING OF MEDICATION | ROBINSON, KYLE G | — |
| 18796217 | METHOD AND COMPOSITION FOR TREATING OBESITY | OLSEN, KAELEIGH ELIZABETH | — |
| 18728814 | PHARMACEUTICAL COMPOSITIONS AND METHODS | HIBBERT, CATHERINE S | — |
| 18440382 | USE OF ULTRARAPID ACTING INSULIN | CHANDRA, GYAN | — |
| Art Unit | Apps |
|---|---|
| 1616 | 2 |
| 3685 | 1 |
| 1656 | 1 |
| 1612 | 1 |
| 1627 | 1 |
| 1619 | 1 |
| 1693 | 1 |
| 1614 | 1 |
| 1615 | 1 |
| 1624 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18861479 | METHOD AND COMPOSITION FOR TREATING LUNG DISEASES | TCHERKASSKAYA, OLGA V | — | §101§103§112 | Non-Final OA | — | Pending | Oct 29, 2024 |
| 18847985 | OPTIMIZATION OF DOSING AND PRESCRIBING OF MEDICATION | ROBINSON, KYLE G | 3685 | §101§103§112 | Final Rejection | — | Pending | Sep 17, 2024 |
| 18796217 | METHOD AND COMPOSITION FOR TREATING OBESITY | OLSEN, KAELEIGH ELIZABETH | — | §103§112Other | Non-Final OA | — | Pending | Aug 06, 2024 |
| 18728814 | PHARMACEUTICAL COMPOSITIONS AND METHODS | HIBBERT, CATHERINE S | — | §102§112DP | Non-Final OA | — | Pending | Jul 12, 2024 |
| 18440382 | USE OF ULTRARAPID ACTING INSULIN | CHANDRA, GYAN | — | §102§103DP | Non-Final OA | — | Pending | Feb 13, 2024 |
| 18434301 | DELIVERY OF ACTIVE AGENTS | HOLLAND, PAUL J | 1656 | §103 | Non-Final OA | — | Pending | Feb 06, 2024 |
| 18367118 | METHOD FOR IMPROVING THE PHARMACEUTIC PROPERTIES OF MICROPARTICLES COMPRISING DIKETOPIPERAZINE AND AN ACTIVE AGENT | WEBB, WALTER E | 1612 | Other | Non-Final OA | 34d | Pending | Sep 12, 2023 |
| 18265660 | Method and Composition for Treating Pulmonary Fibrosis | PIHONAK, SARAH | 1627 | DP | Final Rejection | 61d | Pending | Jun 06, 2023 |
| 17983915 | DRY POWDER INHALER | HAGHIGHATIAN, MINA | 1616 | §103DP | Non-Final OA | 1d overdue | Pending | Nov 09, 2022 |
| 17996706 | CLOFAZIMINE COMPOSITION AND METHOD FOR THE TREATMENT OR PROPHYLAXIS OF VIRAL INFECTIONS | OLSEN, KAELEIGH ELIZABETH | 1619 | §103§112 | Non-Final OA | — | Pending | Oct 20, 2022 |
| 17864828 | Delivery of Active Agents | KRISHNAN, GANAPATHY | 1693 | Other | Final Rejection | 22d | Pending | Jul 14, 2022 |
| 17755425 | Compositions of Clofazimine, Combinations Comprising Them, Processes for Their Preparation, Uses and Methods of Treatment Comprising Them | ARNOLD, ERNST V | 1614 | §103§112 | Non-Final OA | — | Pending | Apr 28, 2022 |
| 17392361 | REACTOR FOR PRODUCING PHARMACEUTICAL PARTICLES IN A PRECIPITATION PROCESS | HELM, CARALYNNE E | 1615 | §103 | Final Rejection | — | Pending | Aug 03, 2021 |
| 17158997 | DRY POWDER INHALER | HAGHIGHATIAN, MINA | 1616 | §103DP | Final Rejection | — | Pending | Jan 26, 2021 |
| 17016158 | METHOD AND COMPOSITION FOR ADMINISTERING PROSTAGLANDINS | MCDOWELL, BRIAN E | 1624 | §103§112 | Non-Final OA | 9d | Pending | Sep 09, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial